Loading...
Pharmacological or TRIB3-Mediated Suppression of ATF4 Transcriptional Activity Promotes Hepatoma Cell Resistance to Proteasome Inhibitor Bortezomib
SIMPLE SUMMARY: Proteasome inhibitors are currently used in the treatment of certain blood cancers, and clinical trials to treat solid tumors, including liver cancer, have also been conducted. However, different malignancies are not equally susceptible to proteasome inhibitors, and resistance to the...
Saved in:
| Published in: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
MDPI
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8150958/ https://ncbi.nlm.nih.gov/pubmed/34066165 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13102341 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|